|
|
|
|
|||||
|
|
|
New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.
DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.
To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Contacts:
Investors
Keyur Parekh
[email protected]
Media
Stephanie Lee
[email protected]
| Jan-23 | |
| Jan-15 | |
| Jan-12 | |
| Dec-17 | |
| Dec-15 |
Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse
IMVT
Investor's Business Daily
|
| Dec-11 | |
| Dec-10 | |
| Nov-29 | |
| Nov-11 | |
| Nov-10 | |
| Oct-31 | |
| Oct-27 | |
| Oct-08 | |
| Sep-30 | |
| Sep-10 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite